Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2025-01-06 Legal Proceedings Report
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 6, 2025, announcing that the Paris Commercial Court declared ACTICOR BIOTECH in 'liquidation proceedings' on January 2, 2025. It explicitly states that the company's shares 'will not be listed again, and Euronext will shortly be asked to delist them.' The core subject is a major corporate event—liquidation and subsequent delisting. While liquidation is a significant event, the most direct classification among the provided options that covers the consequence of the court's decision regarding the stock exchange listing is 'Delisting Announcement' (DLST). Although it is an announcement of a major corporate event, the explicit mention of the impending delisting makes DLST the most precise fit over a general Regulatory Filing (RNS) or a general Capital/Financing Update (CAP).
2025-01-06 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 6, 2025, announcing that the Paris Commercial Court pronounced the judicial liquidation ('liquidation judiciaire') of ACTICOR BIOTECH on January 2, 2025. This is a significant corporate event concerning the company's legal status and cessation of operations, which directly impacts its existence and stock listing (mentioning the upcoming delisting request). This type of critical, non-periodic corporate event announcement, especially one related to insolvency or major legal/structural changes that aren't standard financial reports (10-K, IR, ER), often falls under general Regulatory Filings (RNS) or, if a specific category existed for insolvency/delisting, that would be preferred. Since 'Delisting Announcement' (DLST) is for the *notice* of delisting, and this is the announcement of the *cause* leading to it (liquidation), and there is no specific 'Insolvency Filing' code, RNS (Regulatory Filings) is the most appropriate general category for this mandatory, non-standard regulatory disclosure. The document length is short (under 5,000 characters) and it is an announcement, not the full legal filing itself.
2025-01-06 French
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 95% confidence The document is a press release from Acticor Biotech, dated December 19, 2024, announcing that the Commercial Court of Paris has deferred its judgment regarding the conversion of judicial reorganization into judicial liquidation until January 2, 2025. This is a specific, time-sensitive announcement concerning a legal/regulatory proceeding (judicial reorganization/liquidation) that significantly impacts the company's status and trading. It is not a full annual report (10-K), an earnings release (ER), or a standard quarterly report (IR). Since it directly relates to a significant legal matter and its immediate consequences (like the trading halt), it fits best under 'Legal Proceedings Report' (LTR) or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the focus on the court's decision regarding its legal status, LTR is the most specific fit among the provided options for updates on significant lawsuits or regulatory actions, even though this is a commercial court proceeding. However, LTR is defined as 'Legal Proceedings Report (LTR): Updates on significant lawsuits, regulatory actions, or legal matters involving the company.' This clearly covers the judicial proceedings mentioned. It is a specific update, not a general regulatory filing fallback (RNS).
2024-12-19 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 98% confidence The document is a press release titled "Acticor Biotech announces that the Court judgment has been postponed until January 2, 2025." It discusses a legal proceeding (receivership conversion to liquidation) and the resulting postponement of a court judgment. This content directly relates to significant legal matters involving the company. Based on the definitions, this fits best under 'Legal Proceedings Report' (LTR), as it is an update on a significant lawsuit/regulatory/legal matter. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific legal event.
2024-12-19 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release from Acticor Biotech dated December 10, 2024, announcing a significant legal/procedural event: the judicial administrator has requested the conversion of the company's 'redressement judiciaire' (reorganization/restructuring proceedings) into 'liquidation judiciaire' (judicial liquidation). This is a critical legal and financial event concerning the company's operational status and solvency. It is not a standard periodic financial report (10-K, IR, ER), a management change (MANG), or a dividend announcement (DIV). Since it details a significant legal proceeding impacting the company's existence, it best fits the 'Legal Proceedings Report' (LTR) category, which covers significant lawsuits or regulatory actions, although this is a court-mandated proceeding. Given the options, LTR is the most appropriate fit for a major legal/insolvency status update, as it is a report on a significant legal matter involving the company. It is not a general regulatory filing (RNS) because it is highly specific to a legal process.
2024-12-10 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 10, 2024, announcing that the court-appointed administrator has filed a request to convert receivership proceedings into liquidation proceedings for Acticor Biotech. This is a significant legal and corporate event concerning the company's operational status and legal standing. It is not a standard periodic financial report (like 10-K or IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A/PSI). It relates to legal proceedings and corporate status changes. Among the provided codes, 'Legal Proceedings Report' (LTR) is the closest fit as it concerns significant legal/regulatory action impacting the company's structure, although it is specifically about insolvency/receivership conversion. Since it is a formal announcement of a legal development, LTR is the most appropriate classification, as it is not a general regulatory filing (RNS) but a specific legal update.
2024-12-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.